Research

Comments

Comments received on the draft Human Rights Guidelines for Pharmaceutical Companies in relation to Access to Medicines

• South African Human Rights Commission
• Government of the United States of America
• Oxfam International
• Anja Rudiger, National Economic and Social Rights Initiative (NESRI)
• HelpAge International
• Joint submission from Medact and Wemos
• Niels Ingerslev, Denmark Amnesty International
• Beverly Snell, Centre for International health, Australia
• Professor John S Yudkin, Emeritus Professor of Medicine, University College London
• Robert Weissman, Essential Action
• David Dubins, Assistant Professor, University of Toronto
• Franciscans International
• Health GAP (Global Access Project)
• Health Action International (HAI)
• Robert Reinhard, Community Advisory Board Member
• additional comments
• BioIndustry Association (BIA)
• Global Russian American Health Alliance (GRAHA)
• Suerie Moon, Doctoral Research Fellow, Centre for International Development, Harvard University
• cover letter
• American Autoimmune Related Disease Association (AARDA)
• additional information
• Alliance for Health Education and Development (AHEAD)
• Community Development Medicinal Unit
• Elisabeth Strohscheidt, Menschenrechtsreferentin, Human Rights Desk
• Harvey Bale, International Federation of Pharmaceutical Manufacturers and Associations
• additional information
• Action Against AIDS, Germany
• The AIDS Institute
• cover letter
• additional information
• MERCK
• Shin Furuya, Asia Pacific Equities
• Novo Nordisk
• Dr. Selina Namchee Lo, Independent Specialist
• International Commission of Jurists
• Government of Japan
• F&C Management Limited
• cover letter
• additional information
• Henderson Global Investors
• Catherine Royce
• GlaxoSmithKline (GSK)